Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.61 |
| ▸ | TRPM8 | Q7Z2W7 | 15/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278156 | 0.91 | ADORA2A (0.54) | ADORA2AADORA1TRPM8 | |
| SCHEMBL4283731 | 0.86 | ADORA2A (0.47) | ADORA2AADORA1TRPM8 | |
| SCHEMBL4278140 | 0.85 | ADORA2A (0.51) | ADORA2AADORA1 | |
| SCHEMBL1450009 | 0.82 | ADORA2A (0.61) | ADORA2AADORA1TRPM8 | |
| SCHEMBL5508760 | 0.80 | ADORA2A (0.82) | ADORA2AADORA1TRPM8 | |
| SCHEMBL1449367 | 0.79 | ADORA2A (0.83) | ADORA2AADORA1 | |
| Cyclopropane SCHEMBL15484716 | 0.78 | ADORA2A (0.79) | ADORA2AADORA1TRPM8 | |
| Cyclohexane SCHEMBL15484642 | 0.78 | ADORA2A (0.79) | ADORA2AADORA1TRPM8 | |
| SCHEMBL1449376 | 0.77 | ADORA2A (0.77) | ADORA2AADORA1TRPM8 | |
| SCHEMBL12127937 | 0.77 | ALDH1A1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | claimed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| EP-1794157-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032273-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-30 | — | — | WO | claimed |
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| EP-1794157-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032273-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | ADORA2A, HTR2C, ADORA2B | ADORA2A 1/4885ADORA1 7/4885TRPM8 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.